Market news

Twist Bioscience surged on multiple expansion and AI hype, not fundamentals; AI revenue looks limited and valuation rich. Click for this TWST stock update.

Twist Bioscience shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session.

Twist Bioscience Corporation (NASDAQ:TWST) is on the cusp of gaining significant exposure to the rapidly evolving artificial intelligence (AI)-driven drug discovery ecosystem. On September 16, the company confirmed a strategic partnership with Lilly TuneLab, a platform created by Eli Lilly and Company (NYSE:LLY). As part of the strategic partnership, Twist will provide antibody characterization data […]

It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company.

Twist traded as high as $163.70 on Thursday and finished the session about 9% higher near $156.

On 16 September 2026, Twist Bioscience announced an agreement with Lilly TuneLab, under which Twist will provide antibody characterization data services using preferred Twist protocols to generate high-quality wet lab data that feed Lilly’s AI/ML drug discovery models. This collaboration effectively plugs Twist’s DNA and antibody capabilities into Lilly’s AI-driven discovery ecosystem, potentially deepening Twist’s role in data-rich, AI-enhanced antibody development workflows across the...

(Updates with the latest stock price movement in the headline and the first paragraph.) Twist Bio

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index’s 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services […]

SOUTH SAN FRANCISCO, Calif., September 16, 2026--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model.

Twist Bioscience (TWST) said Wednesday it has agreed to provide antibody characterization data servi

SOUTH SAN FRANCISCO, Calif., September 09, 2026--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026 at 1:25 pm Eastern Time in New York City.

Twist Bioscience (TWST) has an average rating of buy and mean price target of $87.56, according to a

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]

Twist Bioscience Corporation a Hold: $9.5B valuation vs. fundamentals, big surge on AI/short squeeze, guidance raised but losses persist. Click for this TWST update.

Twist Bioscience (TWST) stock jumped, lifting its AI-linked biotech peers after Anthropic said that the company is one of its independent evaluators. Read more here.

Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.

Detailed price information for Twist Bioscience Corp (TWST-Q) from The Globe and Mail including charting and trades.

SOUTH SAN FRANCISCO, Calif., August 05, 2026--Twist Bioscience Corporation (Nasdaq: TWST) ("Twist"), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Twist. The gross proceeds to Twist from the offering, before deducting the underwriting discounts and commission

Moby summary of Twist Bioscience Corporation's Q3 2026 earnings call